Noticias y Actividades de Actinium Pharmaceuticals
Presencia
Sede: Estados Unidos
Actinium Pharmaceuticals es una empresa que cotiza bajo el símbolo de cotización ATNM (US).
Ejecutivos
Ver el organigrama con sus 15 ejecutivos principales
Biografías más buscadas en Actinium Pharmaceuticals
- Sandesh Seth, Chairman of the Board and Chief Executive Officer
- David Nicholson, Lead Independent Director
- Ajit Shetty, Director
Recientes movimientos de ejecutivos en Actinium Pharmaceuticals
- Steffen Heeger, se ha incorporado a la empresa como Chief Medical Officer (noticia publicada el 1 de junio de 2026).
- Steve O'Loughlin, Chief Financial Officer, ha dejado la empresa (noticia publicada el 4 de marzo de 2026).
Crear su alerta
para seguir los movimientos de los ejecutivos en Actinium Pharmaceuticals.
Farmacia
Actinium Pharmaceuticals tiene 1.913 competidores entre los que se incluyen Sanofi (Francia), Eli Lilly (Estados Unidos) y Moderna (Estados Unidos).
Popular M&A news in Farmacia
- Contraline acaba de anunciar una recaudación de fondos de 93 millones de dólares. (publicado el 3 de junio de 2026).
- Hims & Hers ha Eucalyptus adquirido (publicado el 2 de junio de 2026).
- Apotex ha presentado su expediente de OPI. Su símbolo de cotización será TSX. (publicado el 2 de junio de 2026).
Otros contactos sugeridos en el sector Farmacia
Noticias
Últimos comunicados de prensa de Actinium Pharmaceuticals
- Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization :: Actinium Pharmaceuticals, Inc. (ATNM)
- Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting :: Actinium Pharmaceuticals, Inc. (ATNM)
- Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting :: Actinium Pharmaceuticals, In
- Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting :: Actinium Pharmaceuticals, Inc. (ATNM)
- Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting :: Actinium Pharmaceuticals, Inc. (ATNM)
- Press Releases :: Actinium Pharmaceuticals, Inc. (ATNM)
- Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cance
- Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium :: Actinium P
- Actinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor Indications :: Actinium Pharmaceuticals,
- Actinium Pharmaceuticals, Inc. to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference :: Actinium Pharmaceuticals, Inc. (ATNM)
- View more press releases Close
Redes sociales sobre Actinium Pharmaceuticals
- Actinium Pharmaceuticals en Wikipedia, Google News y Yahoo Finance
- Actinium Pharmaceuticals en LinkedIn, Twitter y YouTube
